Citations 0
June 7, 2000

Improving the Conduct and Reporting of Clinical Trials

Author Affiliations

Phil B.FontanarosaMD, Deputy EditorIndividualAuthorStephen J.LurieMD, PhD, Contributing EditorIndividualAuthor


Copyright 2000 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.2000

JAMA. 2000;283(21):2787-2790. doi:10.1001/jama.283.21.2787

To the Editor: In attempting to perform a meta-analysis comparing fluconazole with amphotericin B in neutropenic cancer patients, Drs Johansen and Gøtzsche1 encounted several issues in the drug development process. I wish to comment on 3 of their concerns.

First, the authors question the effectiveness of oral amphotericin B and nystatin as antifungal agents. We agree with their assessment that these agents do not have a role in the treatment of serious systemic fungal infections. In the prophylactic studies described, the intent was to prevent fungal colonization and subsequent infections in high-risk, neutropenic patients with cancer. At the time these studies were conducted in the 1980s and early 1990s, recognized prophylactic antifungal regimens for selective bowel decontamination were oral amphotericin B or nystatin.2 As a result, the medical community deemed a trial of the oral polyenes against the new antifungal agent fluconazole worthwhile and scientifically relevant. Data supporting the use of fluconazole for treatment of systemic fungal infections are based on well-designed treatment studies,3 not the prophylactic studies included in the meta-analysis.

First Page Preview View Large
First page PDF preview
First page PDF preview